Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a validation study that will replicate a completed study designed to assess
biomarkers of treatment response to standard antidepressant treatment. The goal of this study
is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict
treatment outcome for patients experiencing a major depressive episode (MDE).
Phase:
Phase 3
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Baycrest Centre for Addiction and Mental Health Dalhousie University McGill University McMaster University Queen's University Simon Fraser University St. Michael's Hospital, Toronto Unity Health Toronto University of British Columbia University of Calgary University of Michigan University of Ottawa